Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Aligos and Amoytop will use Aligos’ oligonucleotide platform to discover, research and develop oligonucleotides for the treatment of liver diseases in the Greater China territory.
Lead Product(s): Undisclosed
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Aligos Therapeutics
Deal Size: $109.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration May 12, 2023